EFTA
Search
Search
Entities
About
Settings
/
to search
Search
Search syntax help
Dataset
Set 1
Set 2
Set 3
Set 4
Set 5
Set 6
Set 7
Set 8
Set 9
Set 10
Set 11
Set 12
Sort
Relevance
Most pages
Most words
Dataset
Newest
Oldest
Status
All
Extracted
Failed
DOJ Status
All
Removed
Available
Date Range
Undated only
–
Page Count
–
Saved Searches
+
1 result for “
"LCA10"
”
Export
EFTA01100261
Set 9
2016-02-29
39p
20,086w
MORGAN STANLEY RESEARCH Risk Reward Demonstration of safe administration in humans, IP resolution, and
LCA10
success drive risk/reward Investment Thesis BO ■ We are Equal-weight Editas Medicine. The CRISPR ... allow for differentiation over competitors 30 $n t3 ■ The first disease being targeted (
LCA10
, an 20 inherited retinal dystrophy) lowers the initial risk of proving that gene editing can work ... commercialize therapies that Key Value Drivers Bull $72 DCF receive widespread uptake. The
Keyboard Shortcuts
/
Focus search
Esc
Blur input
O
Open PDF
←
→
Paginate
LCA10
therapy launches in the ■ Resolution to IP interference proceedings US and EU in 2024E, treats
https://www.justice.gov/epstein/files/DataSet%209/EFTA01100261.pdf
Corpus: 1990-03-17 – 2025-12-01
←
February 2016
→
Mo
Tu
We
Th
Fr
Sa
Su
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Undated
(150,429)
None
Light
Medium
Heavy
Results by Dataset
1 total
Set 9
1